Bhubaneswar, Oct. 22 -- New Delhi: IAVI, a non-profit scientific research organisation and Serum Institute of India announced an agreement with Merck to develop SARS-CoV-2 neutralising monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the Covid-19 pandemic.

The agreement builds on the advanced antibody discovery and optimization expertise of IAVI and Scripps Research, gained from years of experience in HIV broadly neutralising antibody research and development, and on Merck's and Serum Institute's significant capabilities in design and scale up of accelerated manufacturing processes for mAb production. The global development plan is being led by the three organisations in partner...